FOXO3 and hepatocellular carcinoma: In HCC cells, salinomycin has been shown to function through activating FOXO3 to disturb the β-catenin and TCF complex and inhibiting the expression of β-catenin/TCF target genes (eg. ZEB1, c-Myc and Cyclin D1), involved in CSC development [95].